Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annu...( WAYNE N.J. May 29 /- Bayer Healthcare...),Health

WAYNE, N.J., May 29 /PRNewswire/ -- Bayer Healthcare Pharmaceuticals Inc. today announced that several studies evaluating the use of Leukine(R) (sargramostim) will be presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting.

"We are excited to see that several studies of Leukine have been accepted at ASCO," said Pam Cyrus, MD, vice president, Medical Affairs, Oncology, Bayer HealthCare Pharmaceuticals.

Abstracts are now available on the ASCO Web site at www.abstract.asco.org.

Leukine data highlights include the following:

Chemotherapy-Induced Neutropenia

• Budget impact analysis of sargramostim use in patients with chemotherapy-induced neutropenia
  • Lead investigator: M. Duh, Analysis Group, Inc., Boston, MA
  • Abstract e20596, Publication only

Melanoma

• Immunological effects and clinical outcomes in patients with high-risk melanoma given adjuvant therapy with granulocyte-macrophage colony stimulating factor (GM-CSF, sargramostim)
  • Lead investigator: Lynn Spitler, Northern California Melanoma Center, Saint Mary's Medical Center, San Francisco, CA
  • Abstract e20004, Publication only

Follicular Lymphoma

• Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: Phase III clinical trial results
  • Lead investigator: S. J. Schuster, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
  • Abstract 2, Plenary Presentation, Sunday, May 31, 1:00 PM to 4:00 PM, Level 2, West Hall D2<
    '/>"/>
  
  

  SOURCE Bayer Healthcare Pharmaceuticals Inc. Copyright©2009 PR Newswire. All rights reserved

  2 GOOD

  
  Page: 1 2 3 4
  Related medicine technology :
  
  1. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
  2. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
  3. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
  4. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
  5. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
  6. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
  7. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
  8. Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
  9. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
  10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
  11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer